Allogene Therapeutics, Inc.
General ticker "ALLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $326.3M (TTM average)
Allogene Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -7.1%.
Estimated limits based on current volatility of 4.8%: low 1.36$, high 1.50$
Factors to consider:
- Total employees count: 229 (-1.7%) as of 2024
- Top business risk factors: Market disruptions, Climate change and natural disasters, Operational and conduct risks, Labor/talent shortage/retention, Strategic risks and growth management
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.39$, 3.84$]
- 2025-12-31 to 2026-12-31 estimated range: [1.40$, 3.81$]
Financial Metrics affecting the ALLO estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -50.70 <= 0.33
- Positive: Shareholder equity ratio, % of 76.94 > 63.39
- Positive: Investing cash flow per share per price, % of 19.16 > -0.66
- Positive: Interest expense per share per price, % of 0.05 <= 0.79
- Negative: negative Industry operating cash flow (median)
Short-term ALLO quotes
Long-term ALLO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.16MM | $0.10MM | $0.02MM |
| Operating Expenses | $335.69MM | $327.83MM | $273.22MM |
| Operating Income | $-335.54MM | $-327.74MM | $-273.20MM |
| Non-Operating Income | $-4.88MM | $0.47MM | $16.05MM |
| Interest Expense | $0.00MM | $0.00MM | $0.18MM |
| R&D Expense | $256.39MM | $242.91MM | $192.30MM |
| Income(Loss) | $-340.41MM | $-327.26MM | $-257.15MM |
| Taxes | $0.00MM | $0.00MM | $0.44MM |
| Profit(Loss)* | $-348.20MM | $-327.26MM | $-257.59MM |
| Stockholders Equity | $666.88MM | $512.23MM | $422.18MM |
| Assets | $821.58MM | $642.84MM | $548.71MM |
| Operating Cash Flow | $-220.52MM | $-237.73MM | $-200.30MM |
| Capital expenditure | $5.19MM | $1.52MM | $0.69MM |
| Investing Cash Flow | $106.16MM | $163.29MM | $75.69MM |
| Financing Cash Flow | $2.95MM | $95.69MM | $116.67MM |
| Earnings Per Share** | $-2.43 | $-2.09 | $-1.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.